New drug combo targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests a new drug called RSC-1255, alone or with hydroxychloroquine, in people with advanced solid tumors (like lung, colon, pancreatic cancer, or glioblastoma) that have stopped responding to standard treatments. The goal is to find a safe dose and see if t…
Phase: PHASE1 • Sponsor: RasCal Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 03:08 UTC